Liver Diseases: all 2,094 studies
Page 17 of 21. Open to participants first (390), then studies with results posted, then the rest; newest registration first within each.
- A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic FunctionCompletedNCT02372084Phase 1
- Exercise Intervention in Liver Transplant PatientsCompletedNCT02367092Not applicable
- Nutritional Counseling vs. Nutritional Supplements for NASH - a Randomized Prospective, Open Label Pilot StudyCompletedNCT02366052Phase 2
- Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT02363309
- Vitamin D Improves Depression in Liver PatientsCompletedNCT02359266Not applicable
- Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic SyndromeCompletedNCT02358928Not applicable
- Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and HepatotoxicityStatus unknownNCT02353455
- To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver DiseaseCompletedNCT02347319Phase 4
- Screening of Postoperative Pulmonary Complications by Electrical Impedance TomographyCompletedNCT02337673
- Involvement of Steatosis-induced Glucagon Resistance in HyperglucagonaemiaCompletedNCT02337660Not applicable
- Effect of Probiotics on Gut-Liver Axis of Alcoholic HepatitisStatus unknownNCT02335632Phase 4
- RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic FailureStatus unknownNCT02331745Phase 4
- Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic ResectionCompletedNCT02329821
- The Effects of PXR Activation on Hepatic Fat ContentCompletedNCT02329405Phase 4
- The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study）Status unknownNCT02329314
- Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in ChildrenApproved for marketingNCT02328768
- Gastric- Versus Jejunal Feeding Tubes in Alcoholic Liver DiseasesCompletedNCT02319252Not applicable
- RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health SystemCompletedNCT02312817Not applicable
- Comparing Pain in Patients Undergoing Percutaneous Versus Transjugular Techniques of Liver BiopsyCompletedNCT02311348
- Evaluation of EV1000™/volumeView™ for Cardiac Output Monitoring in Liver TransplantationCompletedNCT02306018
- Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 DiabetesCompletedNCT02303730Phase 4
- Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver DiseaseCompletedNCT02303314Phase 2/3
- Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic FunctionCompletedNCT02296905Phase 1
- Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and MortalityCompletedNCT02294292Not applicable
- Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DMCompletedNCT02289235Early Phase 1
- A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort PharmacokineticsCompletedNCT02286609Phase 1
- Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLDStatus unknownNCT02285218
- A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLDCompletedNCT02285205Phase 4
- The Effect of Pentoxifylline on Liver Function Tests in Fatty Liver DiseaseCompletedNCT02283710Phase 2
- A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using BiomarkersCompletedNCT02272504
- Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver ProgressionCompletedNCT02267148
- A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr DiseaseStatus unknownNCT02265276Phase 3
- Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRIWithdrawnNCT02263677Phase 4
- Temocillin Pharmacokinetics in PaediatricsStatus unknownNCT02260102Phase 4
- Effect of Exercise on Hepatic Fat in Overweight ChildrenCompletedNCT02258126Not applicable
- Effect of Mild Hepatic Impairment on the Pharmacokinetics of IstradefyllineCompletedNCT02256033Phase 1
- "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic PopulationStatus unknownNCT02248311
- Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic ImpairmentCompletedNCT02245243Phase 1
- Pharmacokinetics of WCK 2349 In Patients With Hepatic ImpairmentCompletedNCT02244827Phase 1
- Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic ImpairmentCompletedNCT02242734Phase 1
- Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes SubjectsCompletedNCT02242149Phase 3
- Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy SubjectsCompletedNCT02231450Phase 1
- Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight AdolescentsCompletedNCT02216552Phase 2/3
- Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver DiseaseStatus unknownNCT02213224Phase 4
- Role of Tissue C4d in Differentiation Between Acut e Rejection and HCV Recurrence After Liver TransplantationCompletedNCT02209675Not applicable
- Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 RadioembolizationStatus unknownNCT02208804Phase 2/3
- Potential Role of n-3 Fatty Acids in the Treatment of NAFLD in Pediatric PatientsStatus unknownNCT02201160Phase 1/2
- Study With Heptral in Subjects With Liver Disease Due to Alcohol ConsumptionCompletedNCT02200029Phase 3
- The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease PatientsWithdrawnNCT02194894Not applicable
- Equivalence of New Breath AnalyzerCompared to Currently BreathID System in Assessment of Liver FunctionCompletedNCT02187601Not applicable
- T2 Weighted Imaging of the Liver With Fast Spin Echo MRITerminatedNCT02186054Not applicable
- The Role of Strain Elastography in Staging Liver FibrosisStatus unknownNCT02184000
- The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver DiseaseStatus unknownNCT02178839Not applicable
- Plasma Betatrophin Levels in Non-alcoholic Fatty Liver DiseaseCompletedNCT02176811
- An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe PsoriasisStatus unknownNCT02174367
- Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).CompletedNCT02173080
- Clinical Trial for Evaluation of Treatment With Multiple Infusions of Mononuclear Bone Marrow Cells in Patients With Chronic Liver DiseasesStatus unknownNCT02171949Phase 2
- Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedNCT02171832Phase 1
- Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant PatientsCompletedNCT02166177Phase 1/2
- ALPPS: Safety, Feasibility and Efficacy at a Single CenterCompletedNCT02164292
- Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker DiversityStatus unknownNCT02148562
- Fatty Acids, Genes and Microbiota in Fatty LiverCompletedNCT02148471
- Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM SubjectsCompletedNCT02147925Phase 4
- Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver DiseaseCompletedNCT02140294Not applicable
- Patient-Centered Care and Asian AmericansCompletedNCT02139722Not applicable
- A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in MenCompletedNCT02138162Phase 1
- Autonomic Dysfunction in Non-Alcoholic Fatty Liver DiseaseCompletedNCT02132780
- Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in DiabetesCompletedNCT02132442Phase 3
- Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver DiseaseCompletedNCT02131623
- Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLDStatus unknownNCT02124577
- Omegaven Expanded Access ProtocolNo longer availableNCT02121769
- Analysis of Respiratory System Mechanics and Inflammatory Response During Orthotopic Liver Transplantation (SPPLIT Trial)Status unknownNCT02119585
- Von Willebrand Factor to Predict Postoperative OutcomeCompletedNCT02118545
- Fatty Liver Disease in Obese ChildrenCompletedNCT02117700Phase 1/2
- Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in AdolescentsCompletedNCT02116192Not applicable
- Platelets in Liver RegenerationStatus unknownNCT02113059
- Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care SettingTerminatedNCT02104154
- Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers StudyWithdrawnNCT02098785Phase 1
- Duvelisib in Hepatically Impaired Subjects Compared to Healthy SubjectsCompletedNCT02095587Phase 1
- Prognosis Factors of Cardiac Complications After Liver TransplantationCompletedNCT02087371
- Urinary Metabonomics of Two Major Patterns of NAFLDStatus unknownNCT02077283
- Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLDStatus unknownNCT02075164Not applicable
- To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular CarcinomaStatus unknownNCT02074202Phase 3
- Quantitative Evaluation of the Progression of Liver Disease, Using ShearWaveTMCompletedNCT02070315
- Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver CirrhosisCompletedNCT02068339Phase 3
- MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic FunctionTerminatedNCT02050815Phase 1
- 3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic ShuntsCompletedNCT02046473Not applicable
- Noninvasive Staging of Liver Fibrosis: MR vs UltrasoundCompletedNCT02044523
- Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)Status unknownNCT02038387Not applicable
- Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver TransplantationTerminatedNCT02037373
- The INFECIR-2 Albumin Prevention StudyTerminatedNCT02034279Phase 4
- Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except CirrhosisTerminatedNCT02029586Phase 2
- Influence of Probiotics Administration Before Liver Resection in Liver DiseaseCompletedNCT02021253Not applicable
- Ursodeoxycholic Acid as Treatment for Polycystic Liver DiseaseCompletedNCT02021110Phase 2
- Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic HepatitisCompletedNCT02019056Phase 2
- High Fructose Corn SyrupCompletedNCT02018237Not applicable
- Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic InjuryCompletedNCT02010034Not applicable
- Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT02006498Phase 2
- A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic FunctionCompletedNCT02005744Phase 1
- Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White VolunteersCompletedNCT02004587Phase 1